{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-26-000064","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-10-07T10:11:57+00:00","discovered_at":"2026-10-07T10:15:01.648397+00:00","generated_at":"2026-10-12T16:03:09.820814+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Boston Scientific promotes Joe Fitzgerald to COO; creates three segments Jan 1, 2027","bullets":["Joseph M. Fitzgerald, 63, EVP and Group President, Cardiovascular, promoted to EVP and COO effective Jan 1, 2027; base salary $1,050,000 and 2027 equity award of $7,000,000.","Three reportable segments created effective Jan 1, 2027: Interventional Therapies (Lance Bates), Rhythm Solutions (Nick Spadea-Anello), MedSurg (Stephen Morse), each reporting to Fitzgerald.","Interventional Therapies segment will include the Penumbra business following the anticipated close of that acquisition.","Mark Bickel, 49, named SVP, Global Accounting Controller and Chief Accounting Officer effective March 1, 2027; Emily Woodworth moves to SVP, Global Finance Controller.","CEO Mike Mahoney said the new operating model will create greater capacity to focus on long-term growth priorities and let businesses move faster."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-26-000064","json":"https://secwatch.observer/filing/0000885725-26-000064.json","markdown":"https://secwatch.observer/filing/0000885725-26-000064.md","text":"https://secwatch.observer/filing/0000885725-26-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/0000885725-26-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/bsx-20261001.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:03:09.820814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1616351ce0","claim":"Joe Fitzgerald changed role as Executive Vice President and Chief Operating Officer at BOSTON SCIENTIFIC CORP.","evidence_excerpt":"On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/0000885725-26-000064-index.htm","confidence":0.97,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Executive Vice President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}